Although activating mutations in KRAS alone do not reliably predict the response of colorectal tumours to chemotherapy (Loriot et al, 2009), these findings do suggest that the acquisition of KRAS mutations may be associated with an increased propensity to undergo apoptosis. Here, KRAS is linked to colorectal neoplasm.